Strand Genomics has changed its corporate identity and name as Strand Life Sciences and the new name came into effect coinciding with the launch of its in silico predictive ADMET tool, Admetis.

“The change in corporate identity reflects the expanding focus of the company. Our portfolio of products now extends beyond functional Genomics into computational chemistry,” said Vijay Chandru, CEO and chairman, Strand Life Sciences.

The company has leveraged its core technologies to develop decision-support solutions for powering drug discovery including in silico predictive models for drug properties such as ADME and Cardiotoxicity. In addition, it has an ongoing research programme in predictive modelling for hepatotoxicity. Besides, the company partners with discovery contract research companies in India to combine in silico with wet lab techniques to offer consulting services starting from compound design to lead generation.

Admetis is a comprehensive tool for modelling and predicting drug-relevant properties of molecules in silico. It gives users the power to build custom models from scratch using their own data. This is made possible through easy and intuitive model-building workflows based on Strand's expertise in in silico model building. The product comes packaged with its pre-built models, truPK and truTox, for predicting bio-availability, Protein binding, volume distribution, Elimination half life, Rate of absorption and hERG binding. It also has an extensive data mining and visualization module that supports an embedded chemical structure viewer, said company sources.

According to Kas Subramanian, CSO, Strand Life Sciences, “Admetis couples pre-built models with a workflow-based modelling platform making it a distinct offering. It is a highly intuitive and easy to use tool that helps build accurate predictive models on the fly.”

Strand Life Sciences is a premier in silico technologies and in last five years, developed outstanding technologies in data analytics and predictive modelling in drug discovery and development. “Admetis addresses a key need in the industry and can help profile compounds early,” stated Dr. Chandru.

The company has also developed tools for oligo design, microarray image analysis and has executed several customer specific data analysis projects. Strand partners with discovery contract research companies in India to combine in silico and wet lab techniques to offer consulting services starting from compound design to lead generation.